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Opening the “black box” of informed consent appointments
for genome sequencing: a multisite observational study
Saskia C. Sanderson, PhD1,2, Celine Lewis, PhD1,2, Christine Patch, PhD3,4, Melissa Hill, PhD1,2,
Maria Bitner-Glindzicz, MBBS, PhD1,2 and Lyn S. Chitty, PhD MRCOG1,2
Purpose: Little is known about how health-care professionals
communicate with patients about consenting to genome sequen-
cing. We therefore examined what topics health-care professionals
covered and what questions patients asked during consent
conversations.
Methods: Twenty-one genome sequencing consent appointments
were audio recorded and analyzed. Participants were 35 individuals
being invited to participate in the 100,000 Genomes Project (14
participants with rare diseases, 21 relatives), and 10 health-care
professionals (“consenters”).
Results: Two-thirds of participants’ questions were substantive
(e.g., genetics and inheritance); one-third administrative (e.g., filling
in the consent form). Consenters usually (19/21) emphasized
participant choice about secondary findings, but less often (13/21)
emphasized the uncertainty about associated disease risks. Con-
senters primarily used passive statements and closed-ended, rather
than open-ended, questions to invite participants’ questions and
concerns. In two appointments, one parent expressed negative or
uncertain views about secondary findings, but after discussion with
the other parent opted to receive them.
Conclusion: Health-care professionals need to be prepared to
answer patients’ questions about genetics to facilitate genome
sequencing consent. Health-care professionals’ education also needs
to address how to effectively listen and elicit each patient’s
questions and views, and how to discuss uncertainty around the
disease risks associated with secondary findings.
Genetics in Medicine (2019) 21:1083–1091; https://doi.org/10.1038/s41436-
018-0310-3
Keywords: genome sequencing; next-generation sequencing;
informed consent; education; communication skills
INTRODUCTION
Genome sequencing has the potential to transform much of
health care: genetic diagnoses will potentially be reached far
more quickly than ever before in patients with rare diseases of
unknown cause, reducing “diagnostic odysseys,” and will
eventually lead to improved personalized treatments and
prevention.1 While there is great potential for genome
sequencing to impact rare disease diagnoses and treatments,
there are also practical and ethical challenges. One challenge
is how to support informed consent. The decision for patients
is not always straightforward because potential benefits, e.g.,
diagnosis, need to be weighed against other considerations,
e.g., family implications and data security.2 Individuals also
need to make informed choices regarding secondary findings,
e.g., for disease-predisposing variants.3 The secondary find-
ings issue is one of the most significant ethical challenges
arising from clinical genome sequencing.2,3 Secondary find-
ings decisions are particularly complex given their uncer-
tainty, e.g., variable expressivity of variants in even well-
studied genes such as BRCA1 in individuals from unselected
populations.4
As genome sequencing moves from research to clinical
contexts, as with other investigations, individuals have the
right to consent or not based on communication of under-
standable and adequate information.5 It is important to
understand what approaches are most appropriate for
research and diagnostic genome sequencing consent.
Informed consent is an important cornerstone ensuring
research involving human participants is ethical and respon-
sible, with respect for participants’ autonomy.6 For partici-
pants to provide meaningful informed consent, current UK
National Health Service (NHS) research guidelines emphasize
participants should have in-person conversations with
suitably trained researchers or health-care professionals and
the opportunity to ask questions7 after receiving an informa-
tion sheet, before signing a consent form.
The 100,000 Genomes Project provides a unique framework
within which to begin to explore genome sequencing consent
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for research and clinical care. The genomes of NHS patients
with rare undiagnosed diseases and cancers are being
sequenced to improve diagnoses and treatments, and bring
predicted benefits of genomic medicine to patients.8 It will
also “mainstream” genomics by embedding next-generation
sequencing (including genome sequencing) into the health-
care system, including routine ordering of genomic tests by
clinicians who are not clinical geneticists. In addition to
practical challenges around implementing genome sequencing
on a massive scale, there are numerous ethical and
psychosocial challenges, particularly around informed con-
sent.9 Although the 100,000 Genomes Project information
sheets and consent forms are detailed and standardized, little
is known about the consent conversations. Examining how
consent appointments function in the 100,000 Genomes
Project could shed light on health-care providers’ and
participants’ communication around genome sequencing
consent, and inform policy for integrating genome sequencing
into health care.
A useful methodology to illuminate the “black box” of
consent appointments is the qualitative analysis of appoint-
ment audio or video recordings.10 This can allow analysis of
appointment structure and content and exploration of themes
emerging during the discourse. Examining conversation
content and identifying topics from the information sheet
and/or consent form that are discussed less often may suggest
topics that are challenging to discuss or systematically omitted
for other reasons.
We therefore examined whether and how different types of
information were communicated between consenters and
participants by conducting qualitative analyses of audio-
recorded consent appointments in the rare disease arm of the
100,000 Genomes Project. Our specific aims were to (1)
describe the overarching structure of genome sequencing
consent appointments, (2) describe the content of the genome
sequencing information provided by consenters, (3) explore
what questions potential participants ask about genome
sequencing, and (4) explore the nature and content of
consenter–participant communication around secondary
findings. Our overall objective was to provide insights and
guidance on how discussions about consenting to genome
sequencing could be conducted when used in mainstream
clinical care.
MATERIALS AND METHODS
Study design
This was an observational study involving the audio recording
of in-person consent appointments between health-care
professionals (“consenters”) and potential participants for
the 100,000 Genomes Project. Approval for this study was
obtained from the NHS Research Ethics Committee West
Midlands (15/WM/0258).
Setting
Recruitment was conducted through four London hospitals in
two Genomic Medicine Centres between June 2016 and
January 2017. In the 100,000 Genomes Project, participants
receive genomic information relevant to their condition
(“main finding”). Participants can also consent to “secondary
findings” being looked for and reported. These are variants
associated with serious, life-threatening conditions that can
potentially be prevented, screened for, and/or treated.11 The
genes in which variants will be looked for include those
predisposing to cancer (e.g., BRCA1/2, Lynch syndrome), and
familial hypercholesterolemia. Where both parents partici-
pate, the couple can opt to receive carrier information (cystic
fibrosis).11 Women can opt to receive information about
carrier status for X-linked diseases (Duchenne muscular
dystrophy). (See Supplementary Material for a 100,000
Genomes Project consent form in use at the time of this
study).
Participants and recruitment
This study included consenters responsible for the consent
process, and potential participants (patients with rare diseases
plus their parents/relatives) being recruited to the 100,000
Genomes Project. Consenters have a range of backgrounds
including genetic counseling, research nursing, and other
postgraduate training. All consenters take the online training
course Preparing for the Consent Conversation12 and receive
face-to-face training. Prior to recruitment, potential partici-
pants are identified as eligible by their consultants, who may
provide brief information before referring them to consenters
for more detailed information and discussion.
Consenters were invited to take part in our study and asked
whether they wished to consent. Of 12 consenters invited, 2
declined. To enroll participants, consenters approached
patients prior to consenting them into the 100,000 Genomes
Project, asked if they would be willing to have the
consultation audio recorded, and gave them an information
sheet about our study. Consenters approached participants in
a continuous way so as not to bias the sample. A minimum of
two consenters was recruited at each hospital; each was given
an audio-recording device to record the conversations after
participants had given written consent.
Participants were eligible if they were adult patients with
rare diseases or parents/relatives eligible for the 100,000
Genomes Project including those who accepted, declined, or
deferred the decision; had capacity; were able to read
information materials; and were having the discussion in
English. Of 22 eligible families invited to participate, 1
declined due to distress about their child’s condition.
Recruitment continued until we achieved thematic saturation
as indicated by data redundancy, i.e., when no new themes
emerged.13
Data analysis
We used an interpretative qualitative methodology.14 First, all
audio recordings were transcribed verbatim by external
transcribers, and transcripts were de-identified (e.g., partici-
pant names and hospital site were removed) before the
researchers read them. The research team comprised three
ARTICLE SANDERSON et al
12
34
56
78
9
0(
):,
;
1084 Volume 21 | Number 5 | May 2019 | GENETICS in MEDICINE
postdoctoral researchers (S.C.S., C.L., M.H.) with expertise in
conducting qualitative analyses, and three genetics health-care
providers (C.P., M.B.-G., L.S.C.) of whom two had experience
supervising qualitative analyses. Directed content analysis14,15
was conducted to examine the overarching structure of
appointments. Specifically, each transcript was coded and
categorized independently by two investigators (S.C.S., C.L.)
as being consenter-led or participant-led: transcripts categor-
ized as primarily consenter-led were further examined for
whether participants actively participated, i.e., whether they
expressed their views and/or concerns. The two investigators
then compared codes and disagreements were resolved.
During this analysis phase, consenters’ questions were
identified and coded as either “open-ended” or “closed-
ended.” Thematic analysis was then used to analyze themes,
which involved an iterative process where data were coded,
compared, contrasted, and refined to generate emergent
themes.13 To develop the codebook, one investigator (S.C.S.)
read all transcripts and a second investigator (C.L.) indepen-
dently read a subset; both developed draft codebooks based on
reading and reviewing the same transcript; these were
compared and combined into a single codebook after
discussion. NVivo 10 (QSR International, Australia) was used
to manage the data and facilitate coding. The two investiga-
tors independently coded a second transcript in NVivo;
disagreements were resolved; minor codebook revisions were
made. Each investigator independently coded a third
transcript: the kappa was 0.78 indicating good interrater
agreement; this codebook version was used subsequently. To
ensure rigor and increase authenticity, remaining transcripts
were coded by multiple investigators (S.C.S., C.L., M.H.) with
varying levels of familiarity with genome sequencing, and
emerging themes were checked at multiple timepoints with
the genetics health-care providers and two patient
representatives.
RESULTS
Participants
There were 45 participants: 10 health-care professionals
(consenters), and 35 potential participants in the 100,000
Genomes Project, in 21 consent appointments. All (10/10)
consenters and 16/35 participants were female. See Table 1 for
additional characteristics. In 20/21 appointments all potential
participants consented to take part in the 100,000 Genomes
Project; one adult patient deferred the decision.
Consent appointments: structure
The appointments ranged from 11 to 52 minutes (median 27
minutes). Most (20/21) appointments were consenter-led, i.e.,
consenters led conversations using a structured approach in
which they provided potential participants with information
following the consent form order. Participants actively
participated in the majority (14/20) of these consenter-led
discussions, i.e., participants were involved in the conversa-
tion, expressing their views and/or any concerns. In the other
six consenter-led appointments, however, there was little to
no participant contribution and very little evidence of
participants’ views (Fig. 1). One of these appointments may
have been influenced by the child patient being increasingly
agitated, shouting and screaming, requiring their parents’
Table 1 Consenter and participant characteristics
Characteristics Number (N)
Consenters (total n= 10)
Gender
Female 10
Male 0
Highest level of education/training
No degree: A-levels 1
Undergraduate degree: BA 1
Postgraduate degree: MSc 5
Doctorate degree: PhD 1
Doctorate degree: MD & PhD 1
Job/role
Research assistant or coordinator 7
Research nurse 1
Genetic counselor 1
Geneticist 1
Trained genetic counselor
Yes 1
No 9
Number of consenters at each site
Site 1 2
Site 2 2
Site 3 2
Site 4 4
Participants (total n= 35)
Participant type
Adult with a rare disease 14
Parent of a child with a rare disease 12
Parent of an adult with a rare disease 5
Other relativea of an adult with a rare disease 4
Gender
Female 16
Male 19
Ethnicity
White British/white European 29
Asian 2
Algerian 1
Afghan 1
Black African 1
White British & Asian 1
Age
Range 24 to 70 years, median 46 years
Appointments (total n= 21)
Number of participants present
One adult patient 10
Two parents of a child patient 6
One adult patient and one or more parents/relatives 5
aFor example, a sibling
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attention. One appointment (A13) was participant-led: the
participant deferred his decision; the conversation only
covered a small part of the consent form. This was the
shortest recording (11 minutes).
Consent form topics covered by consenters
Almost all (20/21) consenters verbally covered the following
topics from the written consent form: how personal health
data will be accessed and used, confidentiality, main findings,
participants can withdraw any time. Consent form topics
covering uncertainty about disease risks associated with
secondary findings (13/21), and how participants can change
their minds about secondary findings via opt-in or opt-out
forms (8/21), were covered less frequently (Table 2).
Consenters’ uses of closed-ended versus open-ended
questions
Consenters used closed-ended questions (e.g., “Any ques-
tions?”) to elicit participants’ questions in 12/21 appointments
(totaling 30 instances). Although this sometimes (5/30)
prompted participants to ask questions, most often (25/30)
participants answered “No.” Consenters also used passive
statements to invite participants' questions (e.g., “If you have
any questions just ask”) in 13/21 appointments (totaling 14
instances): these rarely (1/14) elicited an immediate question.
An open-ended question to elicit a participant’s questions,
concerns, or views was used once by one consenter (“How
does that sound?”) and this effectively elicited the view of the
participant, who responded, “That sounds fine to me really,
I’m quite happy for the broader screening as well. I mean I
don’t see that, you know, is there, you know, it’s any help in
the larger picture then I’m quite happy, because as you say I’m
not aware of any other possible condition, but as you say in
life certain things are not, you know, certainly children that’s
not, no longer an issue for me” (A15).
Consenters’ discussion of secondary findings
In 20/21 appointments, consenters provided brief information
about secondary findings. Consenters often (20/21) used
cancer as an example of potential secondary findings,
specifically breast (15/21), colorectal/bowel (11/21), ovarian
(5/21), prostate (3/21), and thyroid (3/21). “Some endocrine
cancers,” “some male cancers,” and “Lynch syndrome” were
referred to once each. Consenters referred to heart disease or
hypercholesterolemia in 11/21 appointments (“a familial
type of high cholesterol,” “some types of high cholesterol,”
“some heart conditions,” “a few heart conditions,”
“hypercholesterolemia”).
In most appointments (19/21), consenters were nondirec-
tive and emphasized secondary findings were optional. In two
of these, consenters explicitly asked participants if they had
any questions (Fig. 2); in three the consenters deliberately
attempted to engage patients in the conversation (e.g., “How
does that sound?” [A15]). In one appointment, the consenter
expressed a personal opinion about secondary findings, i.e.,
was directive: “I personally think it is something positive,
because these are all conditions you can do something about”
(A18). In most appointments (16/21), consenters did not
actively involve participants in conversation about secondary
findings, e.g., in Fig. 1, the consenter talked through the
consent form without pausing or asking the potential
participant about their views regarding secondary findings.
Participants’ questions
Participants in all except one appointment (A20) asked at
least one question. Participants’ questions (109 total) fell into
C: As I’m going through the consent form with you, I will explain everything, which is also covered in the
    information pack… [34 lines of explanation] 
P1: Yep.
C: So, main genetic findings are those which are associated to your condition.... [6 lines of explanation]
There is another, additional box about health-related additional findings. So, there is a number of so-
called risk genes which means genes that are known to cause certain conditions, like breast cancer,
bowel cancer, thyroid cancer, hypercholesterolemia. It doesn’t mean when you have the gene that you
will get the condition—there’s a greater likelihood, because there’s always the interplay between genetic
and environmental factors. However, researchers offer to screen your genome for these conditions, if you
wish so. So, if you would like them to look for so-called risk genes and feed back this result to your
clinician, then you have to indicate yes. Otherwise you indicate no. I personally think it is something
positive, because these are all conditions you can do something about. So for example, let’s say
hypercholesterolemia, this mean a high level of, of fat in the blood, and then you can for example, adjust
your diet. So these are all things you can do something about. And the other point I think most likely is no
longer relevant for you, but in case you were planned to have future offspring, you can get tested for
carrier testing. Otherwise you can just tick it’s not relevant. We just need to mention it for the sake of
completeness. Other findings—so if researchers, for example, find, find a mutation in your genome, it’s
not always horrible because we all have thousands and thousands of mutations in our genome. Not all of them
have an effect.
P1: Well we wouldn’t have [10:05] if we didn’t, would we?
C: We would all be the same. Yeah, exactly. Exactly. So these are so-called silent mutations. And if they
don’t have an effect, these so-called silent mutations, then this is not going to be fed back to the clinician,
because if they have no effect, there is nothing we need to do. Number 13, families members—we try to
recruit family members as well into the study. So, if you have siblings, for example, might be interested in
taking part?
(Appointment 18)
Fig. 1 Fragment illustrating a consenter-led conversation where the participant was not actively involved in the conversation.
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two broad areas with two-thirds (75/109) categorized as
“substantive” and one-third (34/109) “administrative.” Sub-
stantive questions fell into three broad themes, described
below.
Questions about research project details
Questions about research project details were raised in 13/21
appointments. First, participants had questions relating to
practical/procedural aspects of the project, particularly
relating to relatives. Specifically, some parents of children
enrolling wanted to know what would happen regarding their
child consenting and deciding about secondary findings when
they turned 16 years old. Others asked whether and how other
relatives could participate. Second, participants asked ques-
tions reflecting concerns about data access and security
including questions about insurance or private health care,
anonymization/confidentiality, future recontact about other
research, and whether they could participate if they did not
want commercial companies accessing their data. Third,
patients asked questions indicating general interest about the
project, including numbers of people recruited, whether this is
a new project, and how long the research will continue. See
Table S1 for illustrative quotes.
Questions about return of personal results
Participants asked about personal results in 14/21 appoint-
ments: the largest number of these related to secondary
findings (9/21 appointments); fewer to main findings (4/21
appointments) or carrier findings (1/6 relevant
appointments).
Questions about main findings. In two appointments, par-
ticipants asked whether main findings would explain their
child’s condition or inheritance type. One patient asked how
long it would be until they received results. Another patient
expressed concern about communicating main findings to his
daughters, asking whether he could take part without
receiving personal results. In another appointment, partici-
pants asked whether their main findings would be shared with
their general practitioner (GP). See Table S1 for illustrative
quotes.
Questions about health-related secondary findings.
Participants asked about health-related secondary findings in
9/21 appointments, some to check whether they would receive
secondary findings and others about the scope, especially
relating to cancer. Two asked clarifying questions about their
children’s secondary findings: one asked what “childhood
onset conditions” meant; another asked for clarification about
what would happen when their child turned 16.
Questions about carrier secondary findings. Carrier second-
ary findings were potentially relevant in six appointments;
only one participant asked a question.
Questions about genetics and inheritance
In 8/21 appointments, participants asked about genetics
and inheritance. Sometimes (4/21) these were questions to
understand the inheritance patterns for the condition in
their family. Others (3/21) asked questions about general
genetics, specifically how many genes humans have,
and how many genes or whether mitochondrial DNA
might be involved in their condition. In two
Table 2 Frequency with which 100,000 Genomes Project
consent form topics were included in the discussion
Topic Frequency topic
included in discussion
What personal health data will be
accessed and how it will be used
20
All information will be confidential 20
Information about main findings
(including potential benefit to patient)
20
Participant can withdraw any time 20
Participant can choose whether they want
to receive secondary findings
19
Information generated may have
implications for participant's family
members
19
Checking the participant has read the PIS
and/or had opportunity to ask questions
about PIS content
17
Information about giving blood and future
samples
17
Commercial companies can access the
participant’s data
17
The participant may be contacted by the
clinical or project team in the future
17
Results may not be able to provide a
diagnosis or change the participant’s care
17
Results may not be returned in a time
frame that is clinically useful
17
How the participant's samples will be used 16
The participant will not benefit financially 16
Other findings (outside of agreed
secondary findings) will not be routinely
returned
16
Participation in the 100,000 Genomes
Project is voluntary
15
Declining to take part in the 100,000
Genomes Project won’t affect the care the
participant receives
13
Uncertainty about disease risks associated
with secondary findings
13
Participant can change mind about
secondary findings (through opt-in and
opt-out forms)
8
Total n= 21. The consent form sections relating to “carrier status findings” are
not reported here as these were only relevant to a subset of six appointments.
PIS patient information sheet
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appointments, participants asked questions about the
sequencing technology.
Administrative questions
One-third of participants’ questions (34/109) were practical
questions about filling in the consent form, including what to
fill in, which box to tick, who “the patient” and “relations” are.
Participants’ discussion of health-related secondary
findings
Themes arising when participants talked about secondary
findings fell into four categories, described below.
Understanding of health-related secondary findings
In 13/21 appointments, there was insufficient evidence to
make a judgment about whether participants understood the
information about secondary findings. In the 8/21 appoint-
ments where participants did show some understanding, this
was largely limited to understanding that only clinically
actionable findings would be returned (e.g., “Yeah, if it’s
something you can’t treat you won’t tell us?”) (see Table S2).
Positive attitudes toward health-related secondary findings
In nine appointments, participants expressed generally
positive views regarding health-related secondary findings,
e.g., “useful to know” (A10), “brilliant idea” (A11), “quite
happy” (A15). Two participants alluded to this being
empowering. One of these thought the information was
“harmless” (A8), another that it was a novel opportunity (A3).
Negative attitudes toward health-related secondary
findings
In two appointments, both including two parents, one parent
expressed less positive views toward health-related secondary
findings. In the first, the parent expressed concern about
potential adverse psychological impact, e.g., “Yeah, no but
that was what I was meaning, I don’t really want to be going
‘oh, you might have this,' great I’m going to worry about it for
the rest of my life” (A2). In the second, the parent expressed
uncertainty, e.g., “I’m not sure, I’m not sure for me, you can
do what you want but…” (A3) (Table S2).
Participant-to-participant conversation about health-
related secondary findings
In both cases where one parent expressed a negative/uncertain
attitude about health-related secondary findings, this parent
was convinced by the other parent to opt in. In two other
appointments, participant-to-participant conversation about
health-related secondary findings also occurred: these
involved one participant simply telling the other to opt in
(Table S2).
Participants’ discussion of carrier secondary findings
Carrier status information was only relevant in six appoint-
ments: couples talked very little about this. Parents expressed
positive views of the carrier secondary findings in 4/6
appointments but not in great depth, e.g., one just said they
were “quite happy to” (A6). No negative attitudes toward
carrier status information were expressed. In two appoint-
ments, parents evidenced some understanding of what being a
carrier meant; in both cases, this was elicited by the consenter
asking whether they understood what “carrier” meant.
DISCUSSION
Implementation of genome sequencing in mainstream clinical
practice will require clinicians who are not genetics experts to
discuss genome sequencing with patients. In this study we
gained valuable insights into genome sequencing consent
conversations between health-care professionals and patients.
Broadly consistent with clinical research good practice
guidelines, most discussions were consenter-led with active
participant participation: consenters covered many informa-
tion sheet topics, provided opportunities for questions, and
participants expressed their views and/or concerns. The
consenter-led approach increases the likelihood that essential
information is communicated and is consistent with good
C: Point number.10 then. This is the additional findings.  So this is something that is entirely optional. So
since they're looking at whole genome data, which is obviously DNA that controls the whole body, there
are certain genes that they know increase the risk of certain serious or life threatening conditions and part
of this project it’s offering you the chance of knowing if you've got an increased risk towards some of
those conditions where there are treatments available on the NHS. So this is looking at things like breast
cancer, bowel cancer, certain types of inherited heart disease, so if that’s something that you want to
know, if you tick the top box that says yes and then still put your initials in the corner and if you don't want
to know, if you tick the box that says no. Did you have any questions about that at all because obviously
that’s quite an important decision?
P2: [40.41] 
P1: I think that’s brilliant idea. 
P2: They won't tell us.
C: No, exactly.
P2: That’s fine.
C: So the genes they're looking for are only conditions where there are standard NHS treatments
available. So for conditions like Alzheimer's for example, things where there are no treatments available,
that’s only going to stay on an anonymous level, we’re not going to know that at [hospital] and that’s not
going to get fed back to you.
(Appointment 11)
Fig. 2 Fragment illustrating a consenter inviting participants’ questions specifically about secondary findings.
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clinical practice guidelines, as long as patients are actively
encouraged to be part of the conversation.10,16,17
Having the opportunity to ask questions is key to informed
consent,18 but in six appointments patients had little
opportunity to express their concerns, views, or questions.
Previous nongenetics research has similarly found consent
conversations are often recruiter-led, e.g., in a cancer
treatment consent study, 12 of 23 appointments were
recruiter-led.10 In clinical practice, engaging patients in
conversations and eliciting their questions, views, and
evidence of understanding are well-established goals for
patient–clinician communication.19 In genomics, as in other
health-care areas, providers’ training may need to focus more
on these aspects of consent. We found at least one
appointment was often interrupted by a distressed child,
perhaps reflecting particular challenges providers face when
discussing consent in pediatric specialties.
Health-related secondary findings may be returned to 1 in
100 individuals having genome sequencing,11 and participants
could opt in to the principle of receiving clinically actionable
secondary findings (as against the gene list, which may change
over time). Participants’ questions were often about secondary
findings. Although most consenters told participants they
could choose to receive secondary findings, fewer gave other
important information. For example, a minority discussed the
considerable uncertainty around secondary findings (e.g.,
what a BRCA1 pathogenic variant would mean in the absence
of a personal/family history of cancer), or that participants
could opt in or opt out if they later changed their minds.
Additionally, some relatives appeared to instruct others what
to do regarding secondary findings. This emphasizes the need
for health professionals to engage with all family members
when discussing secondary findings, to ensure all make
informed decisions reflecting their own values. Offering
secondary findings will fall outside many health professionals’
expertise, posing a challenge if secondary findings are
similarly offered to patients clinically, e.g., in the newly
commissioned UK NHS genomic medicine service.20 Time is
often pressured in clinical practice, but it is arguably just as
important that patients have adequate information about
secondary findings as about main findings. Health-care
professionals may need to give more time to discussing
secondary findings during genome sequencing consent
conversations, and training for this discussion is a priority
for future education strategies.
Participants less often asked questions about main findings,
perhaps reflecting greater familiarity with the main diagnostic
purpose of genome sequencing compared with the relatively
novel considerations regarding secondary findings. Partici-
pants did ask questions about genetics and inheritance. This
emphasizes the need for the health-care workforce to have
sufficient knowledge to answer such questions or at least
know where to direct patients if they cannot answer
themselves. The 100,000 Genomes Project included invest-
ment in workforce development, recognizing the need to
provide appropriate genomics education and training across
health-care systems.21
Qualitative analysis of audio recordings provided insights
into real-world consent, unlike interviews or focus groups,
and allowed for in-depth exploration not possible in larger
quantitative studies. Nonetheless, the small sample size
limited generalizability. This methodology meant we could
not explore participants’ knowledge or attitudes beyond what
came up naturally in conversations. Additionally, we couldn’t
evaluate whether participants made informed choices.
Because we used audiotapes, body language and other signs
of understanding could not be assessed, e.g., head nodding.
Few previous studies have directly explored communication
around genome sequencing consent. Some have explored
attitudes regarding next-generation sequencing consent using
focus groups,22,23 interviews,23–25 and surveys26 conducted
with participants (mostly parents)22,23,25,26 and health profes-
sionals.22,27–29 These shed some light on stakeholders’
sequencing attitudes and information needs. For example, in
Box 1 Recommendations for health-care professionals discussing genome sequencing with patients as part of the informed consent process
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a mixed-methods study of 25 parents, desire for secondary
findings was high.23 In a survey of 760 health professionals,
many thought secondary findings should be offered.29
Consistent with our study, previous focus group research
found parents were cognizant of risks such as anxiety about
secondary findings.22 Our study builds on previous studies by
examining the actual consent process, allowing us to shed
light on what questions patients actually ask of health
professionals when given the opportunity, and how health
professionals actually communicate with patients about main
and secondary findings.
Our findings highlight issues that need addressing in health
professional training to support genome sequencing consent
processes and implementation. All consenters in the 100,000
Genomes Project underwent 1.5 hours of standardized online
training prior to consenting potential participants, additional
local training and supervision, and continued professional
support.12 Such training undoubtedly is critical in the future
scaling-up of clinical genome sequencing. As the 100,000
Genomes Project is completed, genome sequencing is being
integrated into UK NHS clinical practice for selected
indications. Nongenetics health-care providers need to be
able to talk with patients about next-generation
sequencing–based tests including genome sequencing. Our
findings have implications for consent as genome sequencing
transitions from research to clinical implementation.
Based on our study findings, we recommend standardized
training about next-generation sequencing consent include
greater emphasis on how to engage patients in the conversa-
tion. In the 100,000 Genomes Project consent training,
consenters are informed they should “listen,” give patients
“time to think,” engage in “dialogue not monologue,” and
support patients in making informed decisions. However,
little guidance is given on how to do these things. Health
professionals will need training in more concrete commu-
nication and listening techniques to achieve these goals, e.g.,
the well-established counseling techniques of active listening,
open-ended questions, and ceding the floor30–32 (see Box 1).
Consenters exhibiting these behaviors were more likely to
elicit participants’ views, concerns, and questions. A basic
checklist for health-care providers including guidance such as
“Use open-ended questions to elicit patients’ views, concerns,
and questions” could help ensure patients at minimum have
opportunities to participate and ask questions. Helping
participants/patients make informed choices regarding sec-
ondary findings, e.g., discussing the surrounding uncertainty
and that they can opt in or opt out later on, also needs greater
attention in future education.
A final consideration is that the study was conducted in a
novel hybrid clinical–research setting with dedicated con-
senters. As Wade et al. emphasize, in research, “an inherent
tension exists between safeguarding informed decision-
making by participants and maximising numbers enrolled.”10
The 100,000 Genomes Project differs from traditional
research and future clinical settings where consent conversa-
tions will happen during routine clinical care. However,
certainly in clinical settings in England, future patients will be
invited to consent to their sequence and other data being used
for research as well as personal clinical purposes. Our study
therefore provides insights on genome sequencing consent
that are relevant to future clinical contexts. We conclude that
future health professional training and/or communication/
decision aids about genome sequencing may valuably focus on
secondary findings and skills to increase patients’ active
involvement in the consent process.
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